WuXi Biologics Plans to Sell Irish Vaccine Facility-Related Assets for $500 Million
January 9, 2025
Source: drugdu
111
On January 6, WuXi Biologics announced that the company, along with its indirect wholly-owned subsidiary WuXi Biologics Ireland, has entered into an agreement with MSD International to sell assets related to its Irish vaccine facility for $500 million.
WuXi Biologics stated that the net proceeds from the asset sale will be used for the group’s operational development and general working capital for various regional operations, as well as for potential further share buybacks by the company.
WuXi Biologics primarily provides comprehensive end-to-end vaccine CDMO services and acts as a global biopharmaceutical CRDMO, offering end-to-end solutions for biopharmaceutical discovery, development, and production for clients in the biopharmaceutical industry.
MSD International is a subsidiary of a global pharmaceutical company that provides innovative health solutions through its prescription medicines, vaccines, biologics, and animal health products.
https://finance.eastmoney.com/a/202501073289649267.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Which Strength Training Method Is Best for You? Experts Break Down the Options July 9, 2025
- Is One Type of Water Healthier Than Another? Here’s What Experts Say July 9, 2025
- Innovent Biologics’ Suvicitamab is approved for marketing, solving the dilemma in the treatment of platinum-resistant ovarian cancer July 7, 2025
- Everest Medicines’ Next-Generation BTK Inhibitor EVER001 Announces Latest Clinical Results, Continues to Demonstrate Efficacy and Safety July 7, 2025
- Jinsai Pharmaceutical’s Fuxin Qibaimab was approved, reducing the risk of gout recurrence by 87% in half a year July 7, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
